Also trades as: SABS (NASDAQ) · $vol 2M
SABSW NASDAQ
SAB Biotherapeutics, Inc.
1W: -89.0%
1M: -92.1%
3M: -90.1%
YTD: -96.5%
1Y: -95.8%
3Y: -97.8%
$0.00
-0.00 (-74.42%)
Credit Risk of going bust: lower than 69% of companies Debt: 1.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-21, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-21, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.0477
Volume581,552
Avg Volume115,159
Beta0.53
Dividend—
Analyst Ratings
Company Info
CEOSamuel J. Reich
Employees86
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-25
Websitesab.bio
777 W 41st St.
Miami Beach, FL 33140
US
Miami Beach, FL 33140
US
605-679-6980
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV). Founded in 2014, the company's headquarters are located in Sioux Falls, South Dakota, with a secondary office situated in Cambridge, Massachusetts.
Latest News
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kropotova Alexandra | F-InKind | 988 | — | 2026-03-24 |
| Jain Rita | 0 | — | 2026-01-05 | |
| ZACCARDELLI DAVID | 0 | — | 2026-01-05 | |
| Kropotova Alexandra | F-InKind | 988 | — | 2025-12-11 |
| Moin Andrew | M-Exempt | 17,400 | $1.75 | 2025-09-29 |